Nifurmerone

Nifurmerone

SCHEMBL398798

O=C(CCl)c1ccc([N+](=O)[O-])o1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.51
ALDH1A1 P00352 6/20 0.51
HTT P42858 3/20 0.51
L3MBTL1 Q9Y468 3/20 0.49
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
MITF O75030 2/20 0.49
NFKB1 P19838 3/20 0.48
NFKB2 Q00653 3/20 0.48
RELA Q04206 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
POLB P06746 2/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11455980 0.84 LMNA (0.56) LMNAALDH1A1HTTL3MBTL1RAB9A
SCHEMBL12261479 0.84 LMNA (0.53) LMNAALDH1A1HTTL3MBTL1RAB9A
SCHEMBL11790220 0.82 LMNA (0.51) LMNAALDH1A1HTTL3MBTL1RAB9A
Metofurone SCHEMBL687311 0.79 RAB9A (0.54) LMNAALDH1A1HTTL3MBTL1RAB9A
SCHEMBL11407300 0.79 LMNA (0.56) LMNAALDH1A1HTTL3MBTL1RAB9A
SCHEMBL11407927 0.79 LMNA (0.56) LMNAALDH1A1HTTL3MBTL1RAB9A
SCHEMBL19458000 0.78 GSK3B (0.46) ALDH1A1RAB9ATDP1POLBKDM4E
5-Nitro-2-Furoic Acid SCHEMBL1221377 0.77 LMNA (0.58) LMNAALDH1A1HTTL3MBTL1RAB9A
SCHEMBL14584161 0.77 CASP6 (0.55) LMNAALDH1A1HTTL3MBTL1RAB9A
SCHEMBL11458185 0.77 LMNA (0.54) LMNAALDH1A1HTTL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
CN-1826129-A Methods and compositions relating to isoleucine boroproline compounds POINT THERAPEUTICS INC (US) 2006-08-30 CN claimed
WO-2006081327-A2 SMALL MOLECULES THAT REDUCE FUNGAL GROWTH UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) 2006-08-03 WO claimed
EP-1578434-A2 METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS Point Therapeutics, Inc. (US) 2005-09-28 EP claimed
US-20040131628-A1 Nucleic acids for the treatment of disorders associated with microorganisms BRATZLER ROBERT L (US) 2004-07-08 US claimed
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds POINT THERAPEUTICS, INC. 2004-04-22 US claimed
WO-2004004658-A2 METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS POINT THERAPEUTICS, INC. (US) 2004-01-15 WO claimed
EP-4706683-A2 CHEWABLE FORMULATIONS Elanco Tiergesundheit AG (CH) 2026-03-11 EP disclosed
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES AQUESTIVE THERAPEUTICS, INC. (US) 2026-02-05 US disclosed
US-20250346906-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE ALNYLAM PHARMACEUTICALS INC (US) 2025-11-13 US disclosed
US-12465564-B2 Oral and nasal compositions and methods of treatment AQUESTIVE THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
WO-2000059490-A2 IMMUNOMODULATING COMPOSITION FOR USE ESPECIALLY IN THE TREATMENT OF INFLAMMATIONS, INFECTIONS AND SURGICAL ADHESIONS GENZYME CORPORATION (US) 2000-10-12 WO disclosed
WO-1999036570-A2 TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE PERICOR SCIENCE INC (US) 1999-07-22 WO disclosed
WO-1999030690-A1 ORAL DELIVERY FORMULATION AXIA THERAPEUTICS, INC. (US) 1999-06-24 WO disclosed
US-5795909-A ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS NEUROMEDICA, INC. (US) 1998-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346906-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE CD274, PDCD1LG2, PDCD4 LMNA 2016/4885ALDH1A1 2685/4885HTT 2170/4885
US-20260034059-A1 ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES SORD, SLC6A13, CACNA1A LMNA 2584/4885ALDH1A1 683/4885HTT 2096/4885
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds BCAT1, BCAT2, APOB LMNA 250/4885ALDH1A1 2720/4885HTT 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.